- Home
- / Taienkang Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Taienkang Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥13.6
2024-10-29
Market Capitalization
¥5.8 B
2024-10-29
Revenue
¥665.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 512.9M | 490.6M | 701.2M | 646.6M | 775.0M | 750.3M | 710.5M | 665.4M |
| Cost of goods sold | 285.7M | 285.3M | 320.3M | 326.0M | 327.4M | 299.7M | 312.5M | 310.1M |
| Gross profit | 227.3M | 205.3M | 380.9M | 320.5M | 448.3M | 451.3M | 398.8M | 356.2M |
| Gross profit margin, % | 44.3% | 41.9% | 54.3% | 49.6% | 57.8% | 60.1% | 56.1% | 53.5% |
| Operating expense total | 102.6M | 121.9M | 159.4M | 162.6M | 221.1M | 227.6M | 238.1M | 284.5M |
| Depreciation and amortization | 17.2M | 19.7M | 22.9M | 27.7M | 32.0M | 46.0M | 53.6M | 64.9M |
| EBITDA | 124.7M | 83.5M | 221.5M | 157.9M | 227.2M | 223.7M | 160.7M | 71.6M |
| EBITDA margin, % | 24.3% | 17.0% | 31.6% | 24.4% | 29.3% | 29.8% | 22.6% | 10.8% |
| EBIT | 107.7M | 69.8M | 201.5M | 141.1M | 195.2M | 178.5M | 107.1M | 1.2M |
| EBIT margin, % | 21.0% | 14.2% | 28.7% | 21.8% | 25.2% | 23.8% | 15.1% | 0.2% |
| Interest income | 3.0M | 4.2M | 675.0K | 601.0K | 9.8M | 8.8M | 6.7M | 3.2M |
| Interest expense | 5.4M | 5.1M | 5.1M | 4.7M | 2.6M | 1.7M | 8.6M | 12.6M |
| Pre tax profit | 103.5M | 67.0M | 197.6M | 137.5M | 207.4M | 192.3M | 105.6M | (8.2M) |
| Income tax expense | 21.2M | 13.3M | 43.8M | 17.5M | 32.8M | 38.8M | 8.5M | (20.9M) |
| Net Income | 82.3M | 53.7M | 153.7M | 120.0M | 174.6M | 153.5M | 97.0M | 12.7M |